The drug-device combination market is expected to reach US $30.8 billion by 2028.
The RSCP program is being promoted in cooperation with MFDS. raising awareness of the regulatory support measure, strengthening the regulatory sciences and harmonize the dialogue between regulators and key stakeholders. We are doing our best to disover and promte safety technologies in the field of combination products, and to advance the regulatory science and create a foundation for innovative growth.